A-share issuance

Founded in 2008, RemeGen develops and sells novel drugs in the areas of autoimmunity, oncology, ophthalmology and other major diseases.

FAST NEWS: RemeGen scales back A-share fundraising plan

The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
9995.HK 688331.SHG

Recent Articles

RELATED ARTICLES

  1. RemeGen as problems and losses pile up
    No respite for RemeGen as problems and losses pile up
    9995.HK 688331.SHG
  2. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
  3. Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  4. Cancer drug maker Genfleet joins Hong Kong IPO influx
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva